We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis Thursday launched a program to provide 15 drugs in Kenya, Ethiopia and Vietnam, with plans to eventually expand to 30 low- and middle-income countries. Read More
A qui tam lawsuit, unsealed Tuesday, alleges that Takeda used a sham clinical trial to obtain FDA approval for a new version of its gout drug Colcrys — raking in hundreds of millions of dollars as a result and delaying generic competition. Read More
The owner of Turing Pharmaceuticals says he will reverse course after raising a public outcry this week by upping the price by 5,000 percent. Read More
Amgen is hoping a Delaware judge will be more agreeable than a California court as it sues Hospira to slow the biosimilar maker from marketing its challenger to Epogen. Read More
Palatin Technologies and its partner Gedeon Richter have terminated their collaboration agreement to develop bremelanotide to treat female sexual dysfunction following last month’s FDA approval of Sprout Pharamceuticals’ Addyi for the same indication. Read More
The two frontrunners for the Democratic presidential nomination, Hillary Clinton and Sen. Bernie Sanders of Vermont, released prescription drug policy proposals on Tuesday that would cut prices and end “pay-for-delay” deals. Read More